Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRNXNASDAQ:KYMRNASDAQ:REPLNASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$32.17-0.5%$30.99$24.10▼$62.53$3.01B0.28847,078 shs678,946 shsKYMRKymera Therapeutics$47.29-2.3%$31.69$19.45▼$53.27$3.08B2.07615,522 shs516,048 shsREPLReplimune Group$9.89+1.1%$8.55$6.44▼$17.00$753.91M0.63909,360 shs1.05 million shsVKTXViking Therapeutics$28.58-1.3%$26.34$18.92▼$81.73$3.21B0.654.05 million shs2.47 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals-2.27%+0.62%-2.97%-7.73%-27.87%KYMRKymera Therapeutics-0.43%+9.33%+50.42%+44.66%+39.98%REPLReplimune Group-3.46%+0.93%+24.43%-17.54%+8.67%VKTXViking Therapeutics-0.65%+7.22%+2.30%-2.62%-45.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRNXCrinetics Pharmaceuticals3.4174 of 5 stars3.50.00.03.72.32.50.0KYMRKymera Therapeutics2.3065 of 5 stars3.53.00.00.02.61.70.0REPLReplimune Group4.4121 of 5 stars3.63.00.04.52.82.50.6VKTXViking Therapeutics4.3355 of 5 stars4.51.00.04.71.63.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRNXCrinetics Pharmaceuticals 2.91Moderate Buy$74.56131.75% UpsideKYMRKymera Therapeutics 3.00Buy$59.8226.50% UpsideREPLReplimune Group 3.14Buy$20.83110.65% UpsideVKTXViking Therapeutics 3.00Buy$87.15204.95% UpsideCurrent Analyst Ratings BreakdownLatest REPL, VKTX, KYMR, and CRNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025KYMRKymera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.006/3/2025KYMRKymera TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$57.00 ➝ $64.006/3/2025KYMRKymera TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$38.00 ➝ $60.006/3/2025KYMRKymera TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$49.00 ➝ $79.006/2/2025KYMRKymera TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$51.006/2/2025REPLReplimune GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $22.005/20/2025KYMRKymera TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$55.005/13/2025KYMRKymera TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$72.00 ➝ $70.005/12/2025KYMRKymera TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$47.00 ➝ $44.005/12/2025KYMRKymera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.00 ➝ $52.004/29/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRNXCrinetics Pharmaceuticals$760K3,963.22N/AN/A$8.07 per share3.99KYMRKymera Therapeutics$58.89M52.30N/AN/A$7.12 per share6.64REPLReplimune GroupN/AN/AN/AN/A$6.26 per shareN/AVKTXViking TherapeuticsN/AN/AN/AN/A$3.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRNXCrinetics Pharmaceuticals-$214.53M-$3.82N/AN/AN/AN/A-36.12%-31.89%8/6/2025 (Estimated)KYMRKymera Therapeutics-$146.96M-$3.10N/AN/AN/A-191.26%-24.96%-20.27%8/6/2025 (Estimated)REPLReplimune Group-$215.79M-$3.07N/AN/AN/AN/A-54.84%-42.97%8/6/2025 (Estimated)VKTXViking Therapeutics-$109.96M-$1.15N/AN/AN/AN/A-11.93%-11.57%7/23/2025 (Estimated)Latest REPL, VKTX, KYMR, and CRNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q4 2025REPLReplimune Group-$0.75-$0.82-$0.07-$0.82N/AN/A5/9/2025Q1 2025KYMRKymera Therapeutics-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 million5/8/2025Q1 2025CRNXCrinetics Pharmaceuticals-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 million4/23/2025Q1 2025VKTXViking Therapeutics-$0.31-$0.41-$0.10-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRNXCrinetics PharmaceuticalsN/A16.3916.38KYMRKymera TherapeuticsN/A8.558.55REPLReplimune Group0.1411.4311.43VKTXViking TherapeuticsN/A36.4736.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRNXCrinetics Pharmaceuticals98.51%KYMRKymera TherapeuticsN/AREPLReplimune Group92.53%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipCRNXCrinetics Pharmaceuticals4.60%KYMRKymera Therapeutics16.01%REPLReplimune Group8.80%VKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRNXCrinetics Pharmaceuticals21093.63 million87.17 millionOptionableKYMRKymera Therapeutics17065.12 million54.52 millionOptionableREPLReplimune Group21077.09 million70.24 millionOptionableVKTXViking Therapeutics20112.31 million106.20 millionOptionableREPL, VKTX, KYMR, and CRNX HeadlinesRecent News About These CompaniesViking Therapeutics (VKTX) Rises on Expected DevelopmentsJune 12 at 8:30 PM | insidermonkey.comViking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to NoteJune 12 at 6:46 PM | zacks.comWe're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash WiselyJune 12 at 8:46 AM | finance.yahoo.comHarbor Capital Advisors Inc. Sells 14,094 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)June 12 at 4:51 AM | marketbeat.comViking Therapeutics Target of Unusually High Options Trading (NASDAQ:VKTX)June 12 at 2:42 AM | americanbankingnews.comBrokers Issue Forecasts for VKTX FY2026 EarningsJune 12 at 1:45 AM | americanbankingnews.comAnalysts Issue Forecasts for VKTX FY2026 EarningsJune 11 at 8:45 AM | marketbeat.comWesbanco Bank Inc. Purchases 12,000 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)June 11 at 4:58 AM | marketbeat.comViking Therapeutics Target of Unusually Large Options Trading (NASDAQ:VKTX)June 10 at 1:04 PM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Up 7.1% - Still a Buy?June 10 at 11:57 AM | marketbeat.comWas Jim Cramer Right to Favor Another Stock Over Viking Therapeutics (VKTX)?June 9 at 12:58 PM | msn.comViking Therapeutics, Inc. (NASDAQ:VKTX) Receives $87.15 Average Price Target from BrokeragesJune 9 at 2:23 AM | americanbankingnews.com1 Stock Down 34% This Year to Buy and HoldJune 8, 2025 | fool.com39,652 Shares in Viking Therapeutics, Inc. (NASDAQ:VKTX) Bought by RFG Advisory LLCJune 6, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of "Buy" by AnalystsJune 6, 2025 | marketbeat.comProfit Investment Management LLC Buys 44,055 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)June 2, 2025 | marketbeat.comDeutsche Bank AG Reduces Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)June 2, 2025 | marketbeat.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires New Shares in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 31, 2025 | marketbeat.comPKO Investment Management Joint Stock Co Purchases Shares of 15,000 Viking Therapeutics, Inc. (NASDAQ:VKTX)May 30, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Shares Up 3.4% - Here's WhyMay 29, 2025 | marketbeat.comLighthouse Financial LLC Acquires Shares of 14,000 Viking Therapeutics, Inc. (NASDAQ:VKTX)May 29, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAnalysts Can't Get Enough of These Little-Known Biopharma StocksBy Nathan Reiff | June 12, 2025View Analysts Can't Get Enough of These Little-Known Biopharma StocksREPL, VKTX, KYMR, and CRNX Company DescriptionsCrinetics Pharmaceuticals NASDAQ:CRNX$32.17 -0.16 (-0.49%) As of 04:00 PM EasternCrinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Kymera Therapeutics NASDAQ:KYMR$47.29 -1.10 (-2.27%) As of 04:00 PM EasternKymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Replimune Group NASDAQ:REPL$9.89 +0.11 (+1.12%) As of 04:00 PM EasternReplimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Viking Therapeutics NASDAQ:VKTX$28.58 -0.37 (-1.28%) As of 04:00 PM EasternViking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
